Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 capsules plus D-1553 tablets in KRAS G12C-mutated advanced or metastatic solid tumors
CTR20254974Phase 2Active
- Sponsor
- Genhouse Bio
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GH21, garsorasib in non-small cell lung cancer (NSCLC), Nonhematologic neoplasms, sponsored by Genhouse Bio. Started Dec 2025; status: active.
02
Drugs
GH21garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254974.